Trends in BRCA Mutation Testing Shifting Toward Unaffected Women
Genetic testing for BRCA gene mutation is increasingly undertaken by women unaffected by breast and/or ovarian cancers.
BRCA Gene Mutation
BRCA Testing, Not Mastectomies, Show Increase After Jolie Editorial
More women tested for the BRCA genes but no corresponding increase in mastectomy rates
RANKL Inhibition May Represent Promising Breast Cancer Prevention Strategy
Research presented at 2016 SABCS showed whether RANKL inhibition could reduce the risk for developing breast cancer in BRCA1 mutation carriers.
Bi-allelic Inactivation Common in BRCA1 and BRCA Breast Cancers
Bi-allelic inactivation of BRCA1 and BRCA2 are frequent events in BRCA1 breast cancers and BRCA2 breast cancers, respectively, according to a study presented at SABCS 2016.
Study Identifies Patients Who May Derive More Benefit From Veliparib
At SABCS 2016, researchers presented study findings demonstrating whether neoadjuvant treatment, PARPi-7, BRCAness, and MP1/2 predict response to veliparib plus carboplatin therapy in patients with high-risk breast cancer.
Novel Pathway Improves Access to Genetic Testing for Women With Ovarian Cancer
Rapid, robust, and affordable genetic testing for patients with ovarian cancer that allows a much larger portion of patients to benefit from personalized cancer management and their relatives to benefit from preventive strategies can be achieved.
Prophylactic Gynecologic Resections Increase Risk for Aggressive Uterine Cancer in BRCA Gene Mutation Carriers
Women who carry the BRCA1 mutation are at increased risk for serous/serous-like endometrial carcinoma after risk-reducing salpingo-oophorectomy. Yet uncertainty exists over the need to perform a full hysterectomy in these women.
BRCA1 Mutations May Raise Risk of Serous and Serous-Like Uterine Cancer
Although overall risk for uterine cancer after risk-reducing salpingo-oophorectomy is not increased, the risk of serous/serous-like endometrial carcinoma is higher for BRCA1+ women.
Cell Changes in Fallopian Tubes of BRCA Mutation Carriers May Lead to Strategies for Preventing Ovarian Cancer
Recognition of early changes in the Fallopian tube cells of BRCA gene mutation carriers may be key to new strategies for preventing ovarian cancer that could also reduce the need for invasive surgery.
Research Shows Potential for Breast Cancer Prevention in BRCA1-Driven Tumors
The drug denosumab, which blocks a bone gene, may also prevent breast cancer caused by a BRCA1 mutation. This already approved drug could be available quickly, and would be the first drug for breast cancer prevention.
- Loading...
Loading...
Loading... 
Loading...